Presentation AHA 2024 Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement Presenter: Chisato Izumi November 17, 2024
News Conference News AHA 2024 ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery Yael L. Maxwell November 17, 2024
News Conference News NY Valves 2024 Long-term Mortality After TAVI Lower With DOACs vs VKAs Todd Neale June 06, 2024
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
Presentation ACC 2022 Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial Presenter: Duk-Woo Park April 04, 2022
News Conference News ESC 2021 ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting Todd Neale August 28, 2021
News Conference News ACC 2020 Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair L.A. McKeown April 07, 2020
News Conference News CRT 2020 Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR L.A. McKeown February 24, 2020
News Opinion Conversations in Cardiology Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC? November 16, 2018